NCT05317416 2026-04-16
MagnetisMM-7
Pfizer
Phase 3 Active not recruiting
Clinical Trials
33 trialsNCT07504458 2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3 Recruiting
NCT05254743 2026-04-01
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
NCT06963216 2026-02-27
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Kedrion S.p.A.
Phase 3 Recruiting
NCT04965493 2026-01-29
BRUIN CLL-322
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05023980 2026-01-22
BRUIN CLL-313
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04662255 2025-05-28
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04666038 2025-04-20
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT01109004 2021-12-09
BMT CTN 0702
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT01777152 2021-11-30
ECHELON-2
Seagen Inc.
Phase 3 Completed
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT02055781 2021-11-18
PAC326
CTI BioPharma
Phase 3 Terminated
NCT02038036 2021-07-20
RESPONSE-2
Novartis
Phase 3 Completed
NCT02218047 2021-06-01
CONTI-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT01100502 2021-05-14
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Seagen Inc.
Phase 3 Completed
NCT00773747 2021-04-30
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT02322320 2020-05-11
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT02292446 2019-07-18
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
Novartis
Phase 3 Completed
NCT03426553 2018-12-24
Clinical Use of Pathogen Reduced Red Blood Cell Suspension
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Completed
NCT01191801 2018-08-22
VALOR
Sunesis Pharmaceuticals
Phase 3 Completed
NCT02155634 2018-04-10
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Celgene
Phase 3 Withdrawn
NCT00000589 2016-11-07
Trial to Reduce Alloimmunization to Platelets (TRAP)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT01511289 2016-02-24
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Il-Yang Pharm. Co., Ltd.
Phase 3 Completed
NCT02523638 2016-02-17
PEN-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT01210716 2013-09-23
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
Fenwal, Inc.
Phase 3 Completed
NCT00074763 2012-08-02
Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00883961 2009-12-23
Exercise Following Autologous Peripheral Blood Stem Cell Transplantation
Charite University, Berlin, Germany
Phase 3 Unknown
NCT00884364 2009-12-23
Exercise During Chemotherapy for Patients With Hematological Malignancies
Charite University, Berlin, Germany
Phase 3 Unknown
NCT00001338 2008-03-04
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 3 Completed